The Global Platelet Rich Plasma Market is projected to reach $1,456.40 million by 2028, from a value of $629.64 million in 2022, by registering a CAGR of 15.0% during the forecast period. Growing sports injuries, a rise in surgical & cosmetic procedures, increasing use of platelet-rich plasma in anti-aging, and platelet-rich plasma for stretch marks are the major factors propelling the growth of the market. However, poor quality controls of test results, high cost of the PRP kits, nerve injuries to the patients, and tissue damage at the time of treatment are hampering the market growth. Moreover, the rise in the breadth and use of PRP therapy among medicare beneficiaries and the spreading medical applications of platelet-rich plasma is creating ample opportunities across the globe.

Recent Developments

In July, 2021, Zimmer Biomet Holdings, Inc. partenered with OSSIS to serve as the exclusive Asia Pacific distributor for its patient-specific 3D printed titanium hip replacement joints. This partnership enable Zimmer Biomet to offer an extensive network of orthopaedic surgeons with an alternative of patient-specific implants framed with a combination of clinical and engineering expertise.

In May 2019, Estar Technologies Ltd. announced that the European Patent Office has revoked the patent of Regen Lab SA’s Platelet Rich Plasma (PRP) patent due to lack of novelty.

In In July 2017, Regenexx announced it merged with Harbor View Medical. Through this, In addition to individual personalized care, they will continue to provide both employers and their employees with cost savings results and successful interventions to orthopedic surgery.

In February 2020, EmCyte acquired Cellmedix Holdings LLC. This acquisition bolsters the intellectual property profile of EmCyte Corporation and expands its product development capabilities. EmCyte’s mission of providing the most powerful and effective autologous regenerative biologics continues with bold new ideas.

In September 2021, Royal Biologics announced that it declared the clearance of FDA 510(k) approval of their Maxx-PRP concentration system. The Maxx-PRP is a patented next-generation concentration product that can be utilized to concentrate the autologous whole blood for the safe and rapid preparation of platelet-rich plasma. The Royal’s Maxx-PRP system offers “customizable formulations” of platelet-rich plasma, thus enabling the clinicians to cure a variety of conditions in the fields like sports medicine, plastic surgery, orthopedics, and regenerative medicine.

Competitive Landscape

Zimmer Biomet, Trinity Biotech plc, Terumo BCT, Inc.;, Stryker, Regenexx, Quidel Corporation, Estar Technologies Ltd, Johnson & Johnson (DePuy Synthes), F. Hoffmann-La Roche Ltd., EmCyte Corporation, Dickinson and Company, Royal Biologics, Bionime Corporation, Becton, Assure Tech. (Hangzhou) Co., Ltd., Arthrex, Inc., ARKRAY, Inc., APEX Biologix, ACON Laboratories, Inc., Abbott are some of the major players in the Global Platelet Rich Plasma Market